This Biotech Is Up 1,500% This Year. Can It Make You Rich in 2021?
Cancer is a tricky disease, and one of its ploys is producing tumors that cloak themselves with an increased level of CD47 -- a protein normally associated with healthy cells. This tells the immune system not to attack, and it turns out this so-called "don't eat me" function is a very effective way for solid cancer tumors to hide in plain sight in our bodies.
In 2010, researchers at Stanford showed how nearly all cancer cells used this tool. By 2015, they had developed an antibody to block the cloaking signal and alert specialized immune cells to attack. One of the many companies using this knowledge to develop cancer treatments is Trillium Therapeutics (NASDAQ: TRIL). The stock is up 15 times in value since the beginning of the year, and given its market cap of only $1.8 billion, the shares might just be getting started.
Image source: Getty Images
Source Fool.com
